MRNA vs SNDK

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 17, 2026

MRNA

42.8
AI Score
VS
SNDK Wins

SNDK

58.1
AI Score

Investment Advisor Scores

MRNA

43score
Recommendation
HOLD

SNDK

58score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA SNDK Winner
Revenue 534.00M 11.28B SNDK
Net Income -2.13B 4.53B SNDK
Net Margin -397.9% 40.1% SNDK
Operating Income -2.20B 5.35B SNDK
ROE -31.4% 32.9% SNDK
ROA -19.4% 26.5% SNDK
Total Assets 10.96B 17.07B SNDK
Cash 1.72B 3.73B SNDK
Current Ratio 2.29 4.78 SNDK
Free Cash Flow -1.25B 4.41B SNDK

Relative Price Performance (Last 90 Days)

MRNA 1M: +125.9% · 3M: +162.9% SNDK 1M: -14.9% · 3M: -23.7%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (54.7% over 20 days), RSI 61

RSI (14): 61.3 · Price: $145.62

SNDK

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -9.0%) with fading momentum, RSI 47

RSI (14): 47.3 · Price: $1519.97

Fundamentals Snapshot

Metric MRNA SNDK
Market Cap
Forward P/E -30.4 7.1
Trailing P/E 21.1
Revenue (TTM)
Revenue Growth 0.0% 3.7%
Gross Margin -0.7% 0.7%
Operating Margin -5.6% 0.8%
EPS -7.82 72.72
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, SNDK is currently the stronger investment candidate, winning 10 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.